



Newbury Pharmaceuticals has entered into a partnership granting access to 6 registered products.

Newbury has signed a contract with AmaroX Limited to represent and distribute their products in Sweden and Denmark. As part of the agreement, Newbury and AmaroX will seek to commercialize certain registered products during 2024 with the ambition to expand the portfolio with more products.

Newbury will act as local representative responsible for all commercial activities whereas AmaroX will be responsible for registration, production and inventory.

“The partnership with AmaroX demonstrates our commitment to being the local champion and alternative partner of choice for companies not being present in the Nordics. This is our second distribution partnership signed within a short period of time – and it further validates our business model.”

For more information, contact:

Lars Minor, CEO
lars.minor@newburypharma.com
Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Attachments

[Newbury Pharmaceuticals has entered into a partnership granting access to 6 registered products.](#)